Hemodialysis remains the predominant form of kidney replacement therapy worldwide, yet mortality, hospitalization, symptom burden, and impaired health-related quality of life remain substantial. Historically, dialysis innovation has emphasized surrogate measures such as solute clearance and biochemical targets. Althoug...
Allen R. Nissenson, Jörgen Hegbrant, Franklin W. Maddux et al.· Journal of the American Soci...· 0 citations
Hemodiafiltration (HDF) with online production of substitution fluid has emerged as kidney replacement therapy and is increasingly adopted worldwide. Recent randomized controlled trials, individual participant data meta-analyses, and large real-world studies have demonstrated that high-volume HDF improves clinical outc...
P. Blankestijn, Sanne Roos, Claudia Barth et al.· Journal of the American Soci...· 0 citations
BACKGROUND
Online hemodiafiltration (HDF) enhances the removal of middle molecules, including large-middle molecules, through the combined action of diffusion and convection. Randomized controlled trials (RCTs) and individual participant data (IPD) meta-analyses demonstrate improved cardiovascular outcomes and, importa...
Giovanni F. M. Strippoli, Giovanni Pellegrino, Jörgen Hegbrant et al.· JN. Journal of Nephrology (M...· 0 citations
Background Patient-reported outcome (PRO) measures are increasingly used in clinical trials and clinical care to assess symptoms, functioning, and health-related quality of life (HRQoL). In dialysis research, instrument-driven approaches that rely on legacy measures may not fully capture outcomes that matter most to pa...
Kathrin I. Fischer, K. Cromm, P. Blankestijn et al.· Frontiers in Nephrology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.